Ascendis Pharma gains amid takeover speculation [Seeking Alpha]
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]